Mobile Cancer Screening Devices Market By Application (Cervical Cancer, Breast Cancer, Oral Cancer and Others), By End User (Home Care Settings, Specialty Clinics and Hospitals) - Growth, Future Prospects & Competitive Analysis, 2019 – 2027
The mobile cancer screening devices market is expected to highlight positive growth at a compounded annual growth rate (CAGR) of 5.6% during the forecast period from 2019 to 2027. The mobile cancer screening devices are well equipped with efficient ergonomic features and are less expensive in comparison to conventional screening devices. The rising prevalence of cancer worldwide and increasing demand for portable screening devices among oncologists consolidate the market's growth for mobile cancer screening devices.
Market Synopsis
The most common cancer type in women worldwide and the burgeoning requirement of early screening to reduce the mortality rate drive the breast cancer market's growth. According to the American Institute for Cancer Research, breast cancer is the most common type of cancer occurring in the female population worldwide. In 2018, approximately 2,088,849 cases were diagnosed for breast cancer throughout the globe. Medical device companies are actively engaged in developing mobile cancer screening devices with excellent ergonomic features, low cost, and quick turnaround time required in early screening to curb the high mortality rate associated with the disease. As per the research findings of the World Health Organization (WHO), cervical cancer is the fourth most common cancer in the female population, and in 2018, around 570,000 new cases were reported worldwide. Oncologists advocate for the use of portable colposcopes in the diagnosis of cervical cancer.
Increased public health awareness about cancer, as well as the low-cost burden associated with cancer treatment, drive up demand for specialty clinics.
Specialty clinics are spearheading the end-user segment for the mobile cancer screening devices market. The chief parameters increasing its demand are rising public health awareness pertaining to cancer and the reduced cost burden associated with cancer treatment. Hospitals will be registering impressive growth during the forecast period owing to the proactive role adopted by government healthcare agencies to fight cancer by providing huge financial aid to promote early cancer diagnosis. A large patient pool suffering from cancer can be enrolled in clinical trial studies to test the accuracy and precision of the novel mobile cancer screening device under investigation.
In North America, market growth is being driven by rising cancer prevalence and the presence of pioneering IT healthcare firms engaged in the development of mobile cancer screening devices.
North America is responsible for 34.5% of the market share and is the leading regional segment for the global mobile screening devices market. The major constituents influencing its proactive market growth are rising prevalence rates of cancer. According to the statistics brought forward by the American Cancer Society (ACS) in 2019, approximately 1,762,450 new cancer cases have been reported. The presence of pioneering IT-healthcare firms actively engaged in the development of mobile cancer screening devices further strengthens the market's growth in the region. Europe is accountable for 29.5% on account of the high mortality rate associated with advanced-stage cancer. According to World Health Organization (WHO) research, 1.9 million people die of cancer in Europe each year as a result of delayed diagnosis and medical intervention. Asia Pacific holds a 16% market share and will be growing at a rapid pace in the near future, owing to emerging startup companies working in collaboration with major players to develop mobile cancer screening devices and a significant rise in the number of specialty clinics engaged in cancer treatment.
Periods of History and Forecast
This research report presents the analysis of each segment from 2017 to 2027, considering 2018 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2019 to 2027.
Report Scope by Segments
The market is segmented by application, end user, and geography. Medical device companies and IT healthcare firms engaged in the development of mobile cancer screening devices are AbDent, Inc., Apteryx, Inc., Breastlight, Braster S.A., Bremen Ltd., Forward Science, MobileODT Ltd., Niramai Health Analytix, TruScreen, and UE LifeSciences.
Key questions are answered in this report.
Which IT healthcare companies are developing mobile cancer screening devices?
What are the latest mergers, acquisitions, and collaborations happening in the mobile cancer screening devices market?
What are the prevalence rate and mortality rate of different types of malignant cancer?
What factors increase the popularity of specialty clinics?
What is the market performance of mobile cancer screening devices in Europe and North America?
Frequently Asked Questions:
The market for Mobile Cancer Screening Devices Market is expected to reach in XX Bn in 2027.
The Mobile Cancer Screening Devices Market is expected to see significant CAGR growth over the coming years, at 5.6%.
The report is forecasted to 2019-2027.
The base year of this report is 2018.
AbDent, Inc.,Apteryx, Inc., Breastlight,Braster S.A., Bremed Ltd., are some of the major players in the global market.
